Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SUSTA DS is an injectable testosterone ester mixture developed and manufactured by March Pharma. It is a small molecule formulation designed to provide a rapid onset of action followed by a sustained release of testosterone into the systemic circulation. The product typically contains a blend of four testosterone esters: testosterone propionate, testosterone phenylpropionate, testosterone isocaproate, and testosterone decanoate. As an androgen receptor agonist, SUSTA DS is primarily indicated for testosterone replacement therapy in males with conditions associated with primary and secondary hypogonadism. By binding to and activating intracellular androgen receptors, it promotes the development and maintenance of male sexual characteristics, increases muscle mass, and improves bone mineral density. The 'DS' designation often refers to a higher concentration or 'Double Strength' formulation compared to standard testosterone mix products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on testosterone mix.